Is CAPRICOR THERAPEUTICS, INC. (CAPR) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.1% / 30% | 10.0% / 30% | 0.7% / 30% | 9.42% / 5% | ✗ NOT HALAL |
| DJIM | 0.1% / 33% | 10.0% / 33% | 0.7% / 33% | 9.42% / 5% | ✗ NOT HALAL |
| MSCI | 0.9% / 33% | 88.9% / 33% | 6.1% / 33% | 9.42% / 5% | ✗ NOT HALAL |
| S&P | 0.1% / 33% | 10.0% / 33% | 0.7% / 33% | 9.42% / 5% | ✗ NOT HALAL |
| FTSE | 0.9% / 33% | 88.9% / 33% | 6.1% / 50% | 9.42% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -46.6% | |
| Return on Assets (ROA) | -25.7% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$40M |
| Free Cash Flow | -$42M |
| Total Debt | $1M |
| Debt-to-Equity | 4.7 |
| Current Ratio | 9.0 |
| Total Assets | $170M |
Price & Trading
| Last Close | $29.95 |
| 50-Day MA | $26.76 |
| 200-Day MA | $15.08 |
| Avg Volume | 1.4M |
| Beta | 0.5 |
|
52-Week Range
$4.30
| |
About CAPRICOR THERAPEUTICS, INC. (CAPR)
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is CAPRICOR THERAPEUTICS, INC. (CAPR) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), CAPRICOR THERAPEUTICS, INC. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is CAPRICOR THERAPEUTICS, INC.'s debt ratio?
CAPRICOR THERAPEUTICS, INC.'s debt ratio is 0.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.9%.
What are CAPRICOR THERAPEUTICS, INC.'s key financial metrics?
CAPRICOR THERAPEUTICS, INC. has a market capitalization of $1.7B. Return on equity stands at -46.6%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.